MedTrace Logo

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

NCT00157248 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 361

Last updated 2014-05-19

Study results available
· View outcomes & findings →

Summary

To determine the long term safety and efficacy of BIBR 1048 in patients with chronic atrial fibrilla tion, with or without concomitant chronic treatment with acetylsalicylic acid (ASA).

Conditions

Interventions

DRUG

dabigatran etexilate

dosage used at study start

DRUG

dabigatran etexilate

dosage used at study start

DRUG

dabigatran etexilate

dosage used at study start

DRUG

dabigatran etexilate

dosage used at study start

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2009-01-31

Countries

  • United States
  • Denmark
  • Netherlands
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00157248 on ClinicalTrials.gov